The impact of diabetes mellitus on renal cell carcinoma prognosis: A meta-analysis of cohort studies

Medicine (United States)

Volumn 94, Issue 26, 2015, Pages

  Chen, Luyao ^a   Li, Hongzhao ^a   Gu, Liangyou ^a   Ma, Xin ^a   Li, Xintao ^a   Gao, Yu ^a   Zhang, Yu ^a   Shen, Donglai ^a   Fan, Yang ^a   Wang, Baojun ^a   Bao, Xu ^b   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; EVALUATION STUDY; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; CARCINOMA, RENAL CELL; COMPLICATION; DIABETES COMPLICATIONS; KIDNEY NEOPLASMS; PROGNOSIS;

CARCINOMA, RENAL CELL; COHORT STUDIES; DIABETES COMPLICATIONS; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 84942525917     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001055     Document Type: Article

References (43)

1. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol. 2007;17:303-308.
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241.
3. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132:625-634.
4. Park YH, Lee JK, Kim KM, et al. Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma. J Urol. 2014;192:1043-1049.
5. Choi SK, Min GE, Jeon SH, et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol. 2013;1:365-368.
6. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
7. Ghorbani A. Clinical and experimental studies on polyherbal formulations for diabetes: current status and future prospective. J Integr Med. 2014;12:336-345.
8. Wang YG, Wang P, Wang B, et al. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014;9:e95485.
9. Cai H, Xu Z, Xu T, et al. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2015;31:336-343.
10. Liao C, Zhang D, Mungo C, et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endome-trial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135:163-171.
11. Psutka SP, Stewart SB, Boorjian SA, et al. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J Urol. 2014;192:1620-1627.
12. Lee YJ, Suh J, Kim M, et al. Is diabetes mellitus associated with cancer specific and overall survival in localized clear cell renal cell carcinoma? J Urol. 2014;191(Suppl 1):e654.
13. Hofner T, Zeier M, Hatiboglu G, et al. The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J Urol. 2014;32:1537-1542.
14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
15. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-341.
16. Wells G, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site. 2012.
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
19. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
20. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120:1986-1992.
21. Suer E, Ozturk E, Gulpinar O, et al. Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer. Korean J Urol. 2013;54:499-503.
22. Saroha S, Uzzo RG, Plimack ER, et al. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013;189:454-461.
23. Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006;24:5017-5024.
24. Park B, Jeong BC, Seo SI, et al. Influence of body mass index, smoking, and blood pressure on survival of patients with surgically-treated, low stage renal cell carcinoma: a 14-year retrospective cohort study. J Korean Med Sci. 2013;28:227-236.
25. Lee S, Hong SK, Kwak C, et al. Prognostic significance of diabetes mellitus in localized renal cell carcinoma. Jpn J Clin Oncol. 2012;42:318-324.
26. Keizman D, Gottfried M, Ish-Shalom M, et al. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist. 2014;19:51-60.
27. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194-202.
28. Ha YS, Kim WT, Yun SJ, et al. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann Surg Oncol. 2013;20:3662-3668.
29. Fukushima H, Masuda H, Yokoyama M, et al. Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol. 2013;43:740-746.
30. Patel HD, Kates M, Pierorazio PM, et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol. 2014;21:1086-1092.
31. Vavallo A, Simone S, Lucarelli G, et al. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore). 2014;93:e183.
32. Simone S, Cariello M, Vavallo A, et al. Diabetes mellitus (DM) reduces survival in patients with renal cell carcinoma (RCC): role of OGG1 and tuberin. Nephrol Dial Transplant. 2012;27:ii57.
33. Washio M, Mori M, Khan M, et al. Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol. 2007;14:393-397.
34. Lam EK, Batty GD, Huxley RR, et al. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. 2011;22:730-738.
35. Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011;54:1013-1018.
36. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.
37. Habib SL, Liang S. Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes. Oncotarget. 2014;5:2542-2550.
38. Zelenko Z, Gallagher EJ. Diabetes and cancer. Endocrinol Metab Clin North Am. 2014;43:167-185.
39. Rosen CJ, Pollak M. Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab. 1999;10:136-141.
40. Dupont J, Pierre A, Froment P, et al. The insulin-like growth factor axis in cell cycle progression. Horm Metab Res. 2003;35:740-750.
41. Cardillo TM, Trisal P, Arrojo R, et al. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer. 2013;13:170.
42. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol. 2000;60:1101-1107.
43. Bao C, Yang X, Xu W, et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J Diabetes Complications. 2013;27:357-364.